Prism Medico

Why is Prism Medico & Pharmacy Ltd falling/rising?

As of 01-Sep, Prism Medico & Pharmacy Ltd's stock price is at 29.12, down 0.61% over the last two days but up 53.26% year-to-date. Despite recent declines, the stock remains above key moving averages and shows increased investor interest, indicating resilience in a generally strong performance trend.

As of 01-Sep, Prism Medico & Pharmacy Ltd's stock price is currently at 29.12, reflecting a decrease of 0.18, or 0.61%. The stock has been experiencing a decline, having fallen consecutively for the last two days, resulting in a total drop of 1.52% during this period. Despite this recent downturn, the stock has shown strong performance over longer time frames, with a year-to-date increase of 53.26% and a one-year increase of 73.23%, significantly outperforming the Sensex, which has declined by 9.71% and 4.26% over the same periods, respectively.<BR><BR>Today, the stock has outperformed its sector by 0.39%, indicating some resilience despite the recent price drop. Additionally, there has been a rise in investor participation, with delivery volume increasing by 1.14% against the five-day average, suggesting that while the stock is currently falling, there is still interest from investors. The stock's price is above its 20-day, 50-day, 100-day, and 200-day moving averages, although it is below its 5-day moving average, which may indicate short-term volatility. Overall, the recent price decline appears to be a short-term fluctuation amidst a generally strong performance trend over the longer term.

Who are in the management team of Prism Medico?

The management team of Prism Medico includes Sameer Gupta (Company Secretary & Compliance Officer), Ramandeep Singh and Sakshi Laller (Whole-time Directors), Simmi Chhabra and Pradeep Kumar (Independent Directors), and Davender Singh and Vishwambhar Dayal Gupta (Directors).

The management team of Prism Medico includes the following individuals:<BR><BR>1. Sameer Gupta - Company Secretary & Compliance Officer<BR>2. Ramandeep Singh - Whole-time Director<BR>3. Simmi Chhabra - Independent Director<BR>4. Davender Singh - Director<BR>5. Pradeep Kumar - Independent Director<BR>6. Sakshi Laller - Whole-time Director<BR>7. Vishwambhar Dayal Gupta - Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does Prism Medico do?

Prism Medico and Pharmacy Ltd is a Micro Cap company in the NBFC sector, originally founded in 1985, with no net profit reported as of June 2026 and a market cap of INR 40 Cr. The company has a debt-equity ratio of 0.00% and a return on equity of -2.53%.

Overview: <BR>Prism Medico and Pharmacy Ltd operates in the Non Banking Financial Company (NBFC) sector and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated as Woolite Mercantile Company Limited in 1985 and changed its name to Prism Medico and Pharmacy Limited on January 9, 2012. The latest quarterly results reported are for June 2026, showing no net profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 40 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: -2.53% <BR>Price-to-Book: 2.61<BR><BR>Contact Details: <BR>Address: D-118 Industrial Area, Phase VII Mohali Punjab : 160055 <BR>Tel: 0172-5020762 <BR>Email: investorgrievancewmcl@gmail.com <BR>Website: http://www.prismmedico.in

Who are the peers of the Prism Medico?

Prism Medico's peers include ARC Finance, Salem Erode Inv., Relic Tech., Sugal & Damani, AD Manum Finance, MSL Global, Amrapali Fincap, HB Stockholdings, Toyam Sports, and Lak. Fin. & Indl. While Prism Medico has below average management risk and capital structure, it boasts the highest 1-year return at 68.10% among its peers.

Peers: The peers of Prism Medico are ARC Finance, Salem Erode Inv., Relic Tech., Sugal & Damani, AD Manum Finance, MSL Global, Amrapali Fincap, HB Stockholdings, Toyam Sports, and Lak. Fin. & Indl.<BR><BR>Quality Snapshot: Excellent management risk is observed at ARC Finance, Salem Erode Inv., Relic Tech., Sugal & Damani, AD Manum Finance, MSL Global, Amrapali Fincap, HB Stockholdings, Toyam Sports, and Lak. Fin. & Indl. Average management risk is found at Sugal & Damani and Toyam Sports. Below Average management risk is noted for Prism Medico, ARC Finance, Salem Erode Inv., Relic Tech., AD Manum Finance, MSL Global, Amrapali Fincap, HB Stockholdings, and Toyam Sports. Growth is excellent at Sugal & Damani and MSL Global, while good growth is seen at ARC Finance and AD Manum Finance. Below Average growth is noted for Prism Medico, Salem Erode Inv., Relic Tech., Amrapali Fincap, HB Stockholdings, and Toyam Sports. Capital Structure is excellent for ARC Finance, Salem Erode Inv., Relic Tech., Sugal & Damani, AD Manum Finance, MSL Global, Amrapali Fincap, HB Stockholdings, Toyam Sports, and Lak. Fin. & Indl., while Prism Medico has a Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Prism Medico at 68.10%, while the peer with the lowest is ARC Finance at -40.48%. Prism Medico's 1-year return is significantly higher than that of its peers. Additionally, several peers, including Amrapali Fincap, HB Stockholdings, Toyam Sports, and others, have negative six-month returns.

How big is Prism Medico?

As of 31st August, Prism Medico & Pharmacy Ltd has a market capitalization of 40.00 Cr, with recent net sales of 41.63 Cr and a net profit loss of 0.55 Cr. Shareholder's funds were 12.91 Cr, and total assets were valued at 21.13 Cr as of March 2019.

As of 31st August, Prism Medico & Pharmacy Ltd has a market capitalization of 40.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 41.63 Cr. However, it experienced a loss of 0.55 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2019, where Shareholder's Funds amounted to 12.91 Cr and Total Assets were valued at 21.13 Cr.

Which are the latest news on Prism Medico?

Should I buy, sell or hold Prism Medico & Pharmacy Ltd?

When is the next results date for Prism Medico & Pharmacy Ltd?

The next results date for Prism Medico & Pharmacy Ltd is 12 August 2026.

The next results date for Prism Medico & Pharmacy Ltd is scheduled for 12 August 2026.

Is Prism Medico overvalued or undervalued?

As of November 20, 2025, Prism Medico is considered undervalued with a valuation grade of very attractive, featuring a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, significantly lower than peers like Max Healthcare and Apollo Hospitals, while maintaining a positive long-term outlook with a 3Y return of 77.32%.

As of 20 November 2025, Prism Medico's valuation grade has moved from fair to very attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, which suggest that the stock is trading at a discount relative to its earnings and book value.<BR><BR>In comparison to its peers, Prism Medico's PE Ratio of 18.81 is markedly lower than that of Max Healthcare, which stands at 80.46, and Apollo Hospitals at 63.94, both of which are classified as very expensive. Additionally, Prism Medico's EV to EBITDA ratio of 11.40 aligns with its valuation grade, reinforcing its attractiveness in the market. Despite recent underperformance against the Sensex, particularly in the 1Y and YTD periods, the long-term outlook remains positive with a 3Y return of 77.32%, suggesting potential for recovery and growth.

How has been the historical performance of Prism Medico?

Prism Medico experienced significant growth in net sales, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, but faced profitability challenges with a declining operating profit margin and a negative profit before tax in Mar'19. Total assets increased to 21.13 Cr, alongside rising liabilities, while cash flow remained stagnant with no reported activity.

Answer:<BR>The historical performance of Prism Medico shows significant growth in net sales over the years, increasing from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. The total operating income followed a similar trend, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. However, the company has faced challenges with profitability, as indicated by the operating profit margin which decreased from 3.33% in Mar'18 to 0.73% in Mar'19, and the profit before tax turned negative at -0.10 Cr in Mar'19 after a positive 0.07 Cr in Mar'18. Despite these challenges, the profit after tax showed a slight recovery to 0.04 Cr in Mar'19 from a loss in the previous years. The total assets increased from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities also rose from 15.80 Cr in Mar'18 to 21.13 Cr in Mar'19, indicating a growing financial base but also increasing obligations. The cash flow results indicate no cash inflow or outflow from operating, investing, or financing activities for the years reported.<BR><BR>Breakdown:<BR>Prism Medico's financial performance has demonstrated a remarkable increase in net sales, which surged from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, reflecting a strong growth trajectory. The total operating income mirrored this growth, reaching 54.73 Cr in Mar'19. However, the company struggled with profitability, as evidenced by a decline in operating profit margin from 3.33% in Mar'18 to 0.73% in Mar'19, and a negative profit before tax of -0.10 Cr in Mar'19, contrasting with a profit of 0.07 Cr in the prior year. Despite these setbacks, the profit after tax improved to 0.04 Cr in Mar'19, following losses in earlier years. On the balance sheet, total assets rose from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities increased correspondingly from 15.80 Cr to 21.13 Cr, indicating a growing but leveraged financial position. The cash flow statements reveal no activity in cash flows from operations, investments, or financing, suggesting a stagnant cash position during this period.

Are Prism Medico latest results good or bad?

Prism Medico's latest results are concerning, showing flat performance for Q4 2024 and a 'Strong Sell' rating from MarketsMOJO. However, there are signs of improvement with significant growth in net sales and profit projected for the next quarter, indicating potential for a turnaround.

Prism Medico's latest financial results indicate a challenging situation. The company reported flat performance for the fourth quarter of 2024, showing no significant changes in its financial metrics. This stagnation has led to a 'Strong Sell' rating from MarketsMOJO, suggesting that the market perceives potential difficulties in the company's growth and operational efficiency.<BR><BR>However, looking ahead, there are signs of improvement in the subsequent quarter ending June 2025. The company experienced a remarkable increase in net sales and standalone net profit, with growth rates of 2,171.43% and 1,550.00%, respectively. This upward trend in financial performance could signal a turnaround, but the initial flat results raise concerns about the company's ability to sustain this momentum.<BR><BR>Overall, while the recent quarterly results are not favorable, the significant growth in the following quarter may provide a glimmer of hope for stakeholders. It will be essential to monitor how Prism Medico navigates its challenges in the evolving healthcare sector.

What is the technical trend for Prism Medico?

As of May 19, 2025, Prism Medico's technical trend is mildly bearish, with mixed signals across time frames from MACD, moving averages, and Bollinger Bands, indicating a lack of strong momentum.

As of 19 May 2025, the technical trend for Prism Medico has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly chart but a mildly bearish signal on the monthly chart, indicating mixed signals across time frames. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall mildly bearish outlook. The Dow Theory shows no clear trend in both weekly and monthly views. Overall, the current technical stance is mildly bearish, reflecting a lack of strong momentum in either direction.

Who are the top shareholders of the Prism Medico?

The top shareholders of Prism Medico are Symbiosis Pharmaceutical Private Limited with 13.99%, followed by public shareholder Vinita Jain at 4.83%. Individual investors collectively own 66.07% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Prism Medico include Symbiosis Pharmaceutical Private Limited, which holds the largest stake at 13.99%. Following that, the highest public shareholder is Vinita Jain, with a holding of 4.83%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 66.07% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Prism Medico declared dividend?

No Dividend History Available